Therapeutic advances in gastroenterology
Cure8 research brief
Why This Matters
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine clinical decision-making.
Who Should Pay Attention
Clinicians choosing or monitoring advanced therapies, researchers developing predictive biomarkers, and patients considering or receiving biologic or targeted IBD treatments.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This systematic review searched MEDLINE, EMBASE and PubMed for primary studies of biomarkers predicting response to advanced therapies in Crohn's disease and ulcerative colitis.
It included 55 studies covering blood, serum, fecal, histological, nutrient, genetic and pharmacokinetic markers and assessed baseline predictors of response to anti-TNF agents, ustekinumab, vedolizumab and ozanimod.
Commonly studied tests included C-reactive protein and fecal calprotectin, but the review concluded there is inconsistent evidence and no biomarker has yet entered clinical use. The report is presented as an abstract-based systematic-review summary (PROSPERO ID CRD42024559652).
Keep In Mind
This entry is based on the article abstract and systematic-review summary available from the journal; the authors note heterogeneity in study methods and cutoff values and call for larger prospective cohorts before biomarkers can be adopted clinically.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTherapeutic advances in gastroenterology
AuthorsRadford S, John A, Latino-Kelly A +6 more
Study typeReview, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 12, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn's? - Medscape
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
Crohn's Disease Market Analysis 2034: Clinical Trials, EMA, - openPR.com
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...